Camilli Massimiliano, Del Buono Marco Giuseppe, Menna Pierantonio, Minotti Giorgio
Department of Cardiovascular and Thoracic Sciences, Catholic University of the Sacred Heart, Rome, Italy.
Department of Medicine, Center for Integrated Research and Unit of Drug Sciences, Campus Bio-Medico University, Via Alvaro Del Portillo 21, 00168, Rome, Italy.
Cardiooncology. 2020 Nov 5;6(1):25. doi: 10.1186/s40959-020-00083-7.
Sacubitril/Valsartan (S/V) is a novel and remarkably effective opportunity to treat heart failure with reduced ejection fraction (HFrEF). However, patients with HFrEF induced by cancer therapy were a priori excluded from the registration study. The value of S/V in this important subgroup of patients needs to be firmly established. In this issue of Cardio-Oncology, Gregorietti et al. report on the effects of S/V in a small group of cancer patients, primarily women with breast cancer treated with anthracyclines. The data are limited but seem to confirm the encouraging results of prior studies, paving the way to foster the use of S/V in cardio-oncology patients and hopefully, to design ad hoc prospective studies in this highly vulnerable population.
沙库巴曲缬沙坦（S/V）是治疗射血分数降低的心力衰竭（HFrEF）的一种新型且极为有效的药物。然而，癌症治疗所致HFrEF患者在注册研究中被预先排除。S/V在这一重要患者亚组中的价值有待明确确立。在本期《心脏肿瘤学》中，格雷戈列蒂等人报告了S/V对一小群癌症患者的影响，主要是接受蒽环类药物治疗的乳腺癌女性患者。数据有限，但似乎证实了先前研究令人鼓舞的结果，为在心脏肿瘤学患者中推广使用S/V铺平了道路，并有望在此高度脆弱人群中设计专门的前瞻性研究。
